PENTAX-MEDICAL
PENTAX Medical today announces the launch of a new high-definition (HD) pulmonology endoscopy system in the European, Middle Eastern & African (EMEA) markets. The new DEFINA system in Pulmonology combines a state-of-the art HD processor with i-scan imaging technology and two highly maneuverable HD bronchoscopes. This powerful combination serves to deliver outstanding HD image quality, which subsequently supports clinical outcomes across the complete range of diagnostic and therapeutic applications.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160701005101/en/
The HD DEFINA system delivers sharp and clear image quality, enabling rapid and highly detailed visualization for the improved evaluation of anatomical details of the bronchial mucosa. This in combination with i-scan technology facilitates the precise detection and demarcation of suspicious areas and assists in characterization of abnormalities to support therapeutic decisions.
Fully complying with increasing hygiene requirements, the new DEFINA system uses disposable accessories to reduce the risk of cross-contamination. It is also STERRAD® compatible, ensuring that it is clear of multidrug resistant and extreme drug resistant Mycobacterium. Further adding to patient safety, the new disposable suction valve is safely attached to the endoscope using a click mechanism that cannot be dislodged. This also delivers strong suction to efficiently remove secretion and control bleeding for precise sampling.
Used in conjunction with the EPK-3000 HD processor, the two HD bronchoscopes (EB15-J10 and EB19-J10) of the DEFINA system in Pulmonology are unmatched in their ergonomic design and ease of operation. The new-design lightweight control body of these J10 scopes has an ergonomically positioned suction valve, angulation levers and remote control buttons. Effortless maneuverability within the bronchus, with easy access even to the right upper lobe of the lung, is made possible due to the bronchoscopes’ 210˚ distal tip deflection and insertion tube flexibility.
Rainer Burkard, President EMEA of PENTAX Medical, commented: “Through our close relations with practising endoscopists worldwide, we have looked to develop a high-definition video endoscope system that delivers the optimum in visualization, providing crystal clarity. We have produced a system that also offers high standards of hygiene and ergonomics for the full range of diagnostic and therapeutic applications in the Pulmonology field. Our new DEFINA system in Pulmonology is engineered to support the delivery of best clinical outcomes and image quality.”
This new DEFINA system in Pulmonology will be commercially available from September 1st 2016 to all EMEA markets, except for Russia. In UK only the two HD bronchoscopes (EB15-J10 and EB19-J10) will be available.
About PENTAX Medical
PENTAX Medical is a division of HOYA Group. Its mission is to improve the standard of patient care and quality of healthcare delivery by providing the best endoscopic products and services with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION, and SIMPLICITY. Through leading edge R&D and manufacturing, PENTAX Medical provides endoscopic imaging devices and solutions to the global medical community. Headquartered in Japan, PENTAX Medical has a worldwide focus and presence with R&D, regional sales, service, and in-country facilities around the globe. For more information, please visit: www.pentaxmedical.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160701005101/en/
Contact:
PENTAX Europe GmbH
Sangeeta Gehlot-Vadher
EMEA PR Manager
T:
+44 (0)1753 792 733
F: +44 (0)1753 792 794
E: sangeeta.gehlot@pentaxmedical.com
W:
www.pentaxmedical.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
SLB Announces First-Quarter 2025 Results; Remains Committed to Return a Minimum of $4 Billion to Shareholders in 202525.4.2025 12:50:00 CEST | Press release
Revenue of $8.49 billion decreased 3% year on year GAAP EPS of $0.58 decreased 22% year on year EPS, excluding charges and credits, of $0.72 decreased 4% year on year Net income attributable to SLB of $797 million decreased 25% year on year Adjusted EBITDA of $2.02 billion decreased 2% year on year Cash flow from operations of $660 million increased $333 million year on year Board approved quarterly cash dividend of $0.285 per share SLB (NYSE: SLB) today announced results for the first-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423635499/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts) Three Months EndedChange Mar. 31, 2025 Dec. 31, 2024 Mar. 31, 2024 Sequential Year-on-year Revenue $8,490 $9,284 $8,707 -9% -3% Income before taxes - GAAP basis $1,063 $1,387 $1,357 -23% -22% Income before taxes margin - GAAP basis 12.5% 14.9%
Corona, The World’s Most Valuable Beer Brand1, Announces Its 100-Year Anniversary with Global Celebration25.4.2025 10:00:00 CEST | Press release
Brand Invites The World to Join the Celebration with Experiences at the Most Epic Beaches on EarthGlobal “Corona 100” Platform Launches with a Legendary Concert at Copacabana Beach, Featuring One of the World’s Top Musical Artists with Millions in Attendance Today, Corona proudly celebrates its 100-year anniversary, a remarkable milestone for the iconic brand that has been synonymous with the beach and enjoyed by consumers worldwide for the past century. Since 1925, Corona has cultivated a deep association with the beach; fully embodying a lifestyle connected to nature and relaxation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425804516/en/ Corona 100 This Is Living Since 1925 In honor of the occasion, Corona invites everyone to live their “beach side” – a.k.a. their best side – at top-tier beach locations across the globe. The Corona 100 platform includes a film highlighting 100 years of beach culture, a definitive l
Ant Group Unveils New Recruitment Initiative for Top AI Talents, Ramping Up AI Innovation Efforts25.4.2025 09:28:00 CEST | Press release
Ant Group today unveiled Plan A, a new recruitment initiative to attract top artificial intelligence researchers, reinforcing its commitment to accelerating AI research and development under the “AI First” corporate strategy. Operating within the framework of Ant Star—Ant Group’s year-round campus recruitment program—Plan A specifically targets AI talents who are ambitious, adaptable, altruistic, and analytical. Outstanding graduates from universities worldwide with STEM majors are encouraged to apply for Plan A. Relevant fields include computer science, software engineering, artificial intelligence, cybersecurity, information and telecommunication engineering, mathematics, statistics, and other emerging interdisciplinary areas. To better foster the development of technological innovators in this new AI era, Plan A offers candidates comprehensive support and resources, including unrestricted access to AI hardware and tailored career paths that allow for significant research freedom. Ad
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom